M. K.]). We also thank Mrs.
INTRODUCTION
Anticancer drugs targeting DNA synthesis in tumors have been widely used in clinical studies. In particular, nucleoside analogs such as 1-β-D-arabinofuranosylcytosine (araC), 2-chloro-2'-deoxyadenosine (CldA), 2',2'-difluorocytidine (gemcitabine) and 5-fluorouracil , have been reported to be effective for cancer therapy (1) (2) (3) . However, some drugs have adverse effects such as nausea, vomiting and diarrhea, inducing severe toxicities (2) . To exclude these effects, a method combining low-dose drug administration and exposure to a low dose of radiation has been a potent strategy for cancer therapy. In fact, gemcitabine and 5-FU have been shown to have radiosensitive effects on tumor cell lines in vitro and in vivo (4) (5) (6) .
Genetic changes in cells that impair their ability to control cell cycling and/or to regulate apoptosis, which are generally part of the tumorigenetic process, can affect the sensitivity of tumor cells to radiation therapy and chemotherapy (7) . Resistance of cells to radiation therapy and chemotherapy has been found in some cancer cell lines with a low propensity for apoptosis (8) . Differences in the length and magnitude of radiation-induced G2/M delay may also be critical determinants of cellular radiosensitivity (9) . In previous studies, we reported that apoptosis was induced through the abrogation of arrest at the G2/M phase in X-irradiated human (MKN28 [TP53 mutated] and MKN45 [TP53 wild]) and murine (colon26) tumor cells, as well as Chinese hamster V79 cells, when X irradiation was combined with a ribonucleoside anticancer drug, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (TAS106, ECyd). This was coupled to the enhancement of the loss of clonogenic survival (10, 11) . In those cases, down-regulation of X-ray-induced expression of survivin, a key molecule related to tumor survival, and the abrogation of the G2/M checkpoint due to the attenuation of CDC2-cyclin B1 kinase activity Yasui et al. p. 4 by TAS106 were responsible for this combined effect. Therefore, it is of interest to investigate whether changing the sensitivity of X-irradiated tumor cells to apoptosis by TAS106 administration significantly contributes to antitumor efficacy, though it has been shown in several studies with cells in vitro and tissues in vivo that changing the sensitivity to apoptosis produces little or no change in the overall sensitivity of the cells or tissues to radiation or anticancer drugs (12) .
The ribonucleoside analogue TAS106, shown in Fig. 1 , was first synthesized in 1995.
It has recently been developed as a novel anticancer drug (13) . This compound is effectively phosphorylated by uridine/cytidine kinase 2 (UCK2), which has higher activity in tumor cells than in normal cells (14, 15) . The resultant metabolite, ECTP, a 5'-triphosphate form of TAS106, inhibits RNA synthesis by competing with cytidine 5'-triphosphate and results in a compound cytotoxic to tumor cells (3, (13) (14) (15) (16) (17) (18) . Since survivin has been reported to attenuate the activities of caspases 3, 7, and/or 9 (19) (20) (21) and to regulate proliferation of tumor cells in association with the mitotic apparatus (19) , its down-regulation by TAS106 is expected to induce significant enhancement of radiation-induced cell death not only in vitro but also in vivo.
The purpose of this study was to investigate the in vivo antitumor efficacy of radiation treatment combined with TAS106 administration to tumor-cell-transplanted mice with special emphasis on the down-regulation of survivin expression.
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METHODS AND MATERIALS

Animals and tumor models
Female BALB/c mice aged 8 to 10 weeks and C.B-17/Icr SCID Jcl mice aged 6 weeks were purchased from Japan SLC, Inc. (Hamamatsu, Japan) and Japan CLEA (Tokyo, Japan), respectively. 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (TAS106) was synthesized as described elsewhere (13) . Five days after the initial measurement, animals were randomized into four groups of 5~7 animals each: (1) no treatment; (2) X irradiation with 2 Gy alone; (3) TAS106 administration alone; (4) combined treatment with X irradiation and TAS106 administration. To determine the optimal time sequencing between X irradiation and TAS106 administration, five combination experiments were performed. Three groups were administered TAS106 3, 6 and 9 h before X irradiation. Two groups were administered TAS106 1 and 6 h after X irradiation. TAS106 was intraperitoneally injected into mice at the amounts of 0.1 mg/kg and 0.5 mg/kg. Transplanted tumors were irradiated using a Shimadzu PANTAK HF-350 X-ray generator at a dose rate of 0.8 Gy/min.
In the case of repetitive treatments, Colon26 tumor-bearing mice were treated with the combination of 0.1 mg/kg TAS106 and 2 Gy of X rays on days 10, 12 and 14 after inoculation.
Terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) staining
Tumor tissues were excised from mice at 2~3 mm under the surface and fixed in 4% buffered formaldehyde. Tumors were embedded in paraffin and sectioned 5-μm thick.
After being deparaffinized and rehydrated, sections were incubated with 20 μg/ml 
Electron microscopic analysis
Tumors from the control and treated groups were perfused with 4% paraformaldehyde and immersed in 3% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.3) at 4°C for 4 h. After being postfixed with 2% osmium tetraoxide at 4°C for 2 h, samples were dehydrated and embedded in epoxy resin. After ultrathin sections (80 nm) were stained with uranyl acetate and lead citrate, they were subjected to electron microscopic observation.
Immunohistochemical analysis of Ki-67, survivin, phospho-ERK1/2 and phospho-Akt
Antigen retrieval was performed with a 0.01 M citrate buffer for 10 min at 121°C. 
Statistical analysis
All results were expressed as the mean±SE. The variance ratio was estimated by the F-test and differences in means of groups were determined by Student's t-test or Welch's t-test.
The minimum level of significance was set at P < 0.05.
RESULTS
In initial experiments, the effects of X irradiation alone and TAS106 alone on tumor growth were examined in transplanted tumors. 2 Gy of X irradiation exerted no statistically significant effect on tumor growth either in Colon26 or MKN45 tumors (Fig. 2) . Thus, the dose of 2 Gy of X rays was chosen to evaluate the antitumor effects of the combined treatment with TAS106. No significant retardation of tumor growth was observed in tumor-bearing mice treated with 0.1 and 0.5 mg/kg TAS106 alone for Colon26 ( Figs. 2A and   B ) and 0.1 mg/kg TAS106 alone for MKN45 ( Fig. 2C ). It exerted some effect on MKN45 tumor growth at 0.5 mg/kg, but this effect was not significant except for those on days 16, 18
and 19 ( Fig. 2D ). No statistically significant loss of body weight, behavioral disorder or atrophy of parenchymatous organs was found in any mice treated with 0.5 mg/kg TAS106, although 10 mg/kg TAS106 caused significant loss of body weight and decrease in locomotor activity (data not shown). From these observations, the amounts of 0.1 mg/kg and 0.5 mg/kg TAS106 were chosen for the therapeutic doses.
Though 2 Gy of X irradiation or 0.1 mg/kg TAS106 alone induced no statistically significant retardation of tumor growth, X irradiation 3 h after TAS106 treatment induced a significant retardation in the tumor growth in the Colon26 tumor model. This retardation was observed from day 12 to day 16 (P < 0.05 on day 12 and P < 0.01 on days 13-16). The inhibition rate was 50.8% on day 15 ( Fig. 2A) . Additionally, the combination of 2 Gy of X irradiation and 0.5 mg/kg TAS106 induced similar retardation in the tumor growth ( Fig. 2B ).
To examine the optimal time sequencing for combining X rays and TAS106, Colon26-tumor-bearing mice were administered 0.5 mg/kg TAS106 at different times before or after X irradiation. The TAS106 administration 6 and 9 h before X irradiation had significant effects on tumor growth (6 h, P < 0.05 on days 13-14 and P < 0.01 on days 15-16; 9 h, P < 0.05 on day 14), but the inhibition rates were smaller than that for TAS106 administration 3 h before X irradiation. Furthermore, TAS106 administration 1 and 6 h after X irradiation did not enhance the tumor radioresponse ( Fig. 2B) . These results suggested that administration before X irradiation was a necessary condition for the enhancement of the tumor radioresponse and that TAS106 administration 3 h before X irradiation was optimal.
In the MKN45 tumor model, 0.1 mg/kg TAS106 could not enhance the radiation-induced inhibition of tumor growth (P > 0.05, Fig. 2C ). However, 0.5 mg/kg TAS106 combined with X rays significantly inhibited the tumor growth (P < 0.05 on days 13-14 and P < 0.01 on days [15] [16] [17] [18] [19] [20] . The inhibition rate was 48.5% on day 20 ( Fig. 2D ). From these observations, the amounts of 0.1 mg/kg and 0.5 mg/kg TAS106 were estimated to be minimally effective doses for Colon26 and MKN45, respectively.
Though a single treatment with X rays and TAS106 had a significant retardative effect on tumor growth, reduction of tumor growth was not observed. To investigate whether repetitive treatments with X rays and TAS106 resulted in greater antitumor efficacy, mice received fractionated treatments at days 10, 12, and 14. Though treatment with X rays alone or TAS106 alone showed a tendency to slightly retard the tumor growth, no reduction of tumor growth was observed (Figs. 3B and C). In these cases, three of the five mice in the control group and one of the five mice in the TAS106-treated group died by day 25. As severe loss of body weight (>10%) without macroscopic and pathological lesions was observed in these mice, cachexia seemed to be responsible for the deaths. On the other hand, mice treated with X-rays/TAS106 three times showed obvious inhibition of tumor growth and, interestingly, tumor reduction was observed in three of the six unlike with a single combined treatment, and all the mice survived the experimental period (Fig. 3D ).
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by TUNEL staining as well as electron microscopic observation to determine the relationship between the induction of apoptosis and the retardation of tumor growth. Figures 4A(b) and (c) show that only a few apoptotic cells appeared after either X irradiation or TAS106 treatment.
In contrast, an obvious increase of apoptotic cells was detected with the combination of X irradiation and TAS106 ( Fig. 4A[d] ). Nuclear structures of Colon26 tumor cells treated with X rays and TAS106 were found to be smaller and accompanied by chromatin condensation, chromatin crescents and nuclear fragmentation, as shown in Fig. 4B . The percentage of TUNEL-positive cells vs. total cells demonstrated a significant increase in apoptotic cells (5.7±1.0% for Colon26, 6.6±0.3% for MKN45) compared to the control (0.8±0.2% for Colon26, 0.6±0.3% for MKN45) ( Fig. 4C ) 1 day after the combined treatment. These results indicated that TAS106 treatment made the X-irradiated tumor cells sensitive to apoptosis.
However, the rate of apoptotic cells seemed to be too low to explain the overall suppression of tumor growth. We examined whether 2 Gy of X irradiation and/or 0.1 mg/kg TAS106 damaged normal tissues as well as tumor tissues, but few TUNEL-positive cells were observed in the epidermis and dermis of all groups (Fig. 4D ). Ki-67-positive cells were 69.7±2.4% (control), 53.6±1.8% (X rays alone), 54.6±4.2% (TAS106 alone), and 28.0±1.5% (X-rays/TAS106) ( Fig. 5B[b] ). These results indicated the possibility that the decrease in the proliferative cells in tumors, especially in MKN45 tumors, was quantitatively responsible for the suppression of the tumor growth. We examined whether TAS106 enhanced the radioresponses of normal tissues due to the inhibition of cell proliferation as in tumor tissues, but TAS106 had no effect on the percentage of Ki-67-positive cells in the basal layer of the epidermis in X-irradiated mice (Fig. 5C ).
To obtain further information about the molecular basis of the inhibition of cell proliferation by TAS106, we examined its effect on the expression of SURVIVIN mRNA by real-time quantitative PCR in MKN45 xenografts (Fig. 6A ). While 2 Gy of X irradiation had little effect on the expression of SURVIVIN mRNA, 0.5 mg/kg TAS106 suppressed SURVIVIN mRNA levels to 0.58 (TAS106 alone) and 0.51 (X-rays/TAS106) at 24 h. Suppressive effects of TAS106 on the expression of survivin at the protein level were also observed at 24h in MKN45 xenografts (Fig. 6B ). X irradiation with 2 Gy alone had little effect on the survivin expression (20.3±1.8%) compared to the control (19.8±2.2%), but it was suppressed to 9.4±0.8% (TAS106 alone) and to 5.6±0.4% (X-rays/TAS106). These results were similar to those shown in Fig. 5 .
Since cell survival and proliferation are closely associated with the activation of kinases like ERK1/2 and Akt, the effects of TAS106 on their activation were examined ( Fig.   7 ). While X irradiation with 2 Gy had little effect on the phosphorylation of ERK1/2 compared to the control (19.7 ± 2.0%), TAS106 inhibited the phosphorylation of ERK1/2 to 8.2±1.7% (TAS106 alone) and 11.2±2.5% (X-rays/TAS106), but there was no significant difference between them. X irradiation with 2 Gy caused no significant inhibition of the phosphorylation of Akt compared to the control, but treatment with 0.5 mg/kg TAS106 largely inhibited the activation of Akt (3.2±0.4% for TAS106 alone and 7.9±1.3% for X-rays/TAS106) (Fig. 7B ). In this case, a significant difference between them was observed, but the reason why the suppressive effect of TAS106 treatment was greater than that of the combined treatment was not fully elucidated. These results differed from those shown in Fig.   5 .
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DISCUSSION
The success of radiation therapy depends on its ability to inhibit cell proliferation and induce cell death (23) . However, many types of tumor cells are resistant to radiation therapy (24) . These tumor cells require high doses for sufficient therapeutic efficacy. Therefore, to increase the cure rate of malignant neoplasms, it is essential to manipulate the radiosensitivity of tumors.
The role of apoptosis in radiation-induced cell killing and its significance as a predictor of tumor cell radiosensitivity have been investigated in several studies (25, 26) .
However, it has also been shown in several studies with cells in vitro and tissues in vivo that changing the sensitivity to apoptosis produces little or no change in the overall sensitivity of the cells or tissues to radiation or anticancer drugs (12) . In the present study, TAS106 treatment increased the sensitivity of cells in tumors to apoptosis, resulting in the enhancement of the suppressive effect of X rays on tumor growth ( Fig. 4 ). This result seemed to prove that the sensitivity to apoptosis is a critical determinant of tumor radiosensitivity, but the rate of the apoptosis induction was somewhat low to explain the suppression of tumor growth.
Immunohistochemical analysis for the cell proliferation marker Ki-67 showed that Ki-67-negative cells were largely induced in the tumors treated with X rays and TAS106 (Fig.   5 ). In this case, the percents of Ki-67-positive cells were about 40% and 70% in control including not only cell proliferation and growth but also apoptosis (29) . Therefore, we examined whether TAS106 suppressed these molecules related to cell proliferation.
Phosphorylation of both ERK1/2 and Akt was inhibited by TAS106 in the MKN45 xenograft as shown in Fig. 7 , but the results were not in accord with that of Ki-67-immunohistochemical analysis of the MKN45 xenograft shown in Fig. 5 . Therefore, the activation of ERK1/2 and Akt might not have been critical for the suppression of the tumor growth.
The radiation-induced cell killing effect is closely associated with the induction of DNA double-strand breaks (30) . TAS106 might contribute to the effective suppression of X-irradiated tumors by interfering with the repair of DNA double-strand breaks. The measurement of the extent of γ-H2AX phospohorylation is used as evidence for the presence of DNA double-strand breaks (31) . However, our preliminary experiments using anti-phosphorylated γ-H2AX showed that there were no differences in the number of foci per cell after X irradiation, TAS106 treatment and X irradiation combined with TAS106 treatment in cultured MKN45 cells (data not shown). Thus, the effective suppression of tumor growth by the combined treatment cannot be attributed to the inhibition of repair of DNA double-strand breaks at present.
X irradiation sometimes induces up-regulation of mRNA levels of various
anti-apoptotic proteins such as survivin, a member of the IAP family, in cancer cells (32) .
Moreover, it has been reported that DNA damage stimulates ATM/ATR followed by the activation of cell-cycle checkpoint kinases 1 and 2 (CHK1 and CHK2) and subsequently by the phosphorylation of CDC25C, and induction of the G2/M checkpoint (33) . Slowly dying cells have a variety of cell cycle arrest profiles and, therefore, differences in the length and magnitude of radiation-induced G2/M delay may be critical determinants of cellular radiosensitivity (9, 34) . In fact, an inhibitor of CHK1, 7-hydroxystaurosporine (UCN-01), was reported to enhance the antitumor activity of ionizing radiation by abrogating the G2/M checkpoint (35) . Manipulation of these factors for cell survival and the G2/M checkpoint seems to be important for tumor radiotherapy.
Since TAS106 is an inhibitor of RNA synthesis (17), we hypothesized that the expression of various proteins causing the resistance of tumor cells to genotoxic agents would be suppressed by TAS106, followed by an increase in the X-ray-killing effect. Our recent experiments demonstrated that TAS106 enhanced not only the induction of apoptosis but also loss of clonogenic ability in X-irradiated tumor cells in vitro, regardless of the difference in TP53 status, at low concentrations causing no cell death (10, 11) . In these studies, TAS106 In conclusion, we demonstrated that an inhibitor of RNA synthesis, TAS106, could potentiate the antitumor activity of X irradiation with 2 Gy for solid tumors. In particular, it is noteworthy that repetitive treatments with the combination of X irradiation and TAS106
induced marked inhibition of tumor growth in half of the mice (Fig. 3) . Although the precise mechanisms for the suppression of the tumor growth in vivo need to be further investigated, a low dose of TAS106 in combination with radiation therapy may be a promising strategy for clinical trials. Panel D: TUNEL assay in skin tissue located in the Colon26 tumor margin. (a) control, (b) tumor exposed to 2 Gy of X rays, (c) tumor exposed to 2 Gy of X-rays/0.1 mg/kg TAS106. control, (b) tumor exposed to 2 Gy of X rays, (c) tumor exposed to 2 Gy of X-rays/0.1 mg/kg TAS106.
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